Wenyuan Shi

Dr. Wenyuan Shi is Chief Executive Officer of the Forsyth Institute and has led the Forsyth Institute since 2017. He also served as Forsyth’s Chief Scientific Officer until Dr. Ben Wu joined the team in 2023. Before his appointment, Shi was the chairman and professor of Oral Biology at UCLA Schools of Dentistry as well as the Professor of Microbiology, Immunology and Molecular Genetics at UCLA School of Medicine for 20+ years.

Dr. Shi has been leading numerous NIH grants to use multidisciplinary approaches to study oral microbial pathogenesis with a specific focus on microbial biofilm, inter-species interaction, and signal transduction. In addition, Dr. Shi’s laboratory is actively involved in the development of the next generation of diagnostic and therapeutic tools against oral microbial infections, including instant chairside detection of oral pathogens and peptide-based targeted antimicrobial therapeutics. These translational research efforts have resulted in novel technologies that were licensed and developed by major pharmaceutical, dental, and biotech companies. Dr. Shi is the founding scientist, former chief scientific officer, and chairman of the scientific advisory board of C3J Therapeutics Inc., which is now called Armata Pharmaceuticals (https://www.armatapharma.com), listed on NYSE.

Dr. Shi obtained his BS degree from Fudan University (Shanghai) in 1984, acquired his Ph.D. degree from the University of Wisconsin-Madison in 1991, and fulfilled his postdoctoral training at the University of California-Berkeley during 1992-1995. He is the co-author and co-inventor of over 200 scientific articles and 40 patents and patent applications.